Print

Lay Description

The goal of this randomized, open labelled clinical trial is to examine the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide versus metformin plus sitagliptin in recently diagnosed type 2 diabetes mellitus patients.
The main question[s] it aims to answer are:
How effective is the combination of pioglitazone plus tirzepatide in managing blood sugar levels in people with type 2 diabetes?
How does this combination compare to the use of metformin plus sitagliptin in controlling blood sugar levels?

Category

  • Diabetes
IRB Number
STUDY00000139
NCT Number
NCT06246799

Eligibility

Eligible Ages
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Gozde Baskoy
210-358-7200
baskoy@uthscsa.edu

Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu

Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu

Principal Investigator
Muhammad Abdul-Ghani